Lacosamide Biogaran

Lacosamide, the active ingredient in Lacosamide Biogaran, is an anticonvulsant presented as a tablet for oral use. It treats partial‑onset seizures and epilepsy in patients who require additional seizure control. GNH USA supplies Lacosamide Biogaran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an anticonvulsant indicated for seizure disorders, particularly focal epilepsy. - Partial‑onset seizures: reduces the frequency of focal seizures when used as adjunctive therapy. - Focal epilepsy: provides additional seizure control in patients not adequately managed by other antiepileptic drugs. - Adjunctive therapy in refractory epilepsy: helps achieve better overall seizure reduction when combined with other agents.

Lacosamide may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Nausea: mild to moderate stomach upset. - Fatigue: feeling unusually tired or weak. - Headache: mild to moderate head pain. - Vision disturbances: blurred or double vision.

Serious or Rare Side Effects: - Cardiac arrhythmia: abnormal heart rhythm, including PR‑interval prolongation. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Suicidal thoughts: emergence of depressive symptoms or suicidal ideation. - Acute pancreatitis: severe abdominal pain with elevated enzymes.

Before initiating Lacosamide therapy, consider the following safety measures. - Cardiac monitoring: assess baseline ECG and monitor for PR‑interval changes. - Renal function: adjust use in patients with severe renal impairment. - Hepatic function: evaluate liver enzymes in patients with hepatic disease. - Pregnancy: avoid use unless potential benefit justifies potential risk to the fetus. - Concomitant CNS depressants: use caution as additive sedation may occur. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Lacosamide can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Carbamazepine: may reduce lacosamide plasma levels, decreasing effectiveness. - Phenytoin: can lower lacosamide concentrations, potentially compromising seizure control.

Moderate Interactions (Monitor Closely): - CYP2C19 inhibitors (e.g., fluconazole): may increase lacosamide exposure, requiring dose adjustment. - CNS depressants (e.g., benzodiazepines, opioids): may enhance sedation and respiratory depression. - Anticoagulants (e.g., warfarin): monitor INR as lacosamide may affect coagulation parameters.